A New Approach to Measuring Estrogen Exposure and Metabolism in Epidemiologic Studies by Ziegler, R. G. et al.
Cedarville University 
DigitalCommons@Cedarville 
Pharmaceutical Sciences Faculty Publications Department of Pharmaceutical Sciences 
8-1-2010 
A New Approach to Measuring Estrogen Exposure and 
Metabolism in Epidemiologic Studies 
R. G. Ziegler 
J. M. Faupel-Badger 
L. Y. Sue 
B. J. Fuhrman 
R. T. Falk 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.cedarville.edu/
pharmaceutical_sciences_publications 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
This Article is brought to you for free and open access by 
DigitalCommons@Cedarville, a service of the Centennial 
Library. It has been accepted for inclusion in 
Pharmaceutical Sciences Faculty Publications by an 
authorized administrator of DigitalCommons@Cedarville. 
For more information, please contact 
digitalcommons@cedarville.edu. 
Authors 
R. G. Ziegler, J. M. Faupel-Badger, L. Y. Sue, B. J. Fuhrman, R. T. Falk, J. Boyd-Morin, M. K. Henderson, R. N. 
Hoover, Timothy D. Veenstra, L. K. Keefer, and X. Xu 
Journal of Steroid Biochemistry & Molecular Biology 121 (2010) 538–545
Contents lists available at ScienceDirect
Journal of Steroid Biochemistry and Molecular Biology
journa l homepage: www.e lsev ier .com/ locate / j sbmb
Review
A new approach to measuring estrogen exposure and metabolism in
epidemiologic studies
R.G. Zieglera,∗, J.M. Faupel-Badgera,b, L.Y. Suea, B.J. Fuhrmana, R.T. Falka, J. Boyd-Morinc,
M.K. Hendersona, R.N. Hoovera, T.D. Veenstrad, L.K. Keefere, X. Xud
a Epidemiology and Biostatistics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA
b Cancer Prevention Fellowship Program, Center for Cancer Training, National Cancer Institute, Bethesda, MD 20892, USA
c Information Management Services, Inc., Silver Spring, MD 20904, USA
d Laboratory of Proteomics and Analytical Technologies, Advanced Technology Program, SAIC-Frederick, Inc., Frederick, MD 21702, USA
e Laboratory of Comparative Carcinogenesis, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA
a r t i c l e i n f o
Article history:
Received 3 December 2009
Received in revised form 22 March 2010
Accepted 23 March 2010
Keywords:
Estradiol
Estrogen metabolism
Estrone
Liquid chromatography–tandem mass
spectrometry
a b s t r a c t
Endogenous estrogen plays an integral role in the etiology of breast and endometrial cancer, and conceiv-
ably ovarian cancer. However, the underlying mechanisms and the importance of patterns of estrogen
metabolism and specific estrogen metabolites have not been adequately explored. Long-standing
hypotheses, derived from laboratory experiments, have not been tested in epidemiologic research
because of the lack of robust, rapid, accurate measurement techniques appropriate for large-scale stud-
ies. We have developed a stable isotope dilution liquid chromatography–tandem mass spectrometry
(LC–MS2)method that canmeasure concurrently all 15 estrogens and estrogenmetabolites (EM) in urine
and serumwithhigh sensitivity (level of detection=2.5–3.0 fmol EM/mLserum), specificity, accuracy, and
precision [laboratory coefficients of variation (CV’s)≤5% for nearly all EM]. The assay requires only extrac-
tion, a single chemical derivatization, and less than 0.5mL of serum or urine. By incorporating enzymatic
hydrolysis, the assaymeasures total (glucuronidated+ sulfated+unconjugated) EM. If the hydrolysis step
is omitted, theassaymeasuresunconjugatedEM. Interindividualdifferences inurinaryEMconcentrations
(pg/mL creatinine), which reflect total EM production, were consistently large, with a range of 10–100-
fold for nearly all EM in premenopausal and postmenopausal women and men. Correlational analyses
indicated that urinary estrone and estradiol, the most commonly measured EM, do not accurately rep-
resent levels of total urinary EM or of the other EM. In serum, all 15 EM were detected as conjugates,
but only 5 were detected in unconjugated form. When we compared our assay methods with indirect
radioimmunoassays for estrone, estradiol, and estriol and enzyme-linked immunosorbent assays for 2-
hydroxyestrone and 16-hydroxyestrone, ranking of individuals agreed well for premenopausal women
[Spearman r (rs) = 0.8–0.9], but only moderately for postmenopausal women (rs = 0.4–0.8). Our absolute
readings were consistently lower, especially at the low concentrations characteristic of postmenopausal
women, possibly because of improved specificity. We are currently applying our EMmeasurement tech-
niques in several epidemiologic studies of premenopausal and postmenopausal breast cancer.
Published by Elsevier Ltd.
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1. Endogenous estrogen and breast, endometrial, and
ovarian cancer
In the last decade, the evidence that endogenous estrogen levels
are causally related to breast cancer has strengthened substan-
tially. In 2002, a pooled analysis of the worldwide data from
prospective studies, which included 663 women who developed
breast cancer and 1765 women who did not, demonstrated that
risk of postmenopausal breast cancer increased significantly (p
for trend <0.001) with increasing circulating concentrations of
estrone sulfate, estrone, and estradiol [1]. For each estrogen, risk
doubled between extreme quintiles. Urinary concentrations of
estrogens have also been positively associated with subsequent
risk of postmenopausal breast cancer, with trends in risk reach-
ing statistical significance [2,3]. However, prospective studies have
not yet conclusively shown an association between circulating or
urinary estrogens and risk of premenopausal breast cancer, quite
possibly because of the complexity of controlling for variation
in estrogen levels during the menstrual cycle [3,4]. Fewer data
exist for endometrial cancer. In the largest prospective study to
date, including 247 incident cases of endometrial cancer and 481
controls from the European Prospective Investigation into Cancer
and Nutrition (EPIC), risk of endometrial cancer increased sig-
nificantly with serum concentrations of estrone and estradiol in
postmenopausal women (p for trend <0.01), but was not clearly
related in premenopausal women [5]. Among postmenopausal
women, associations with endometrial cancer seemed stronger
than thosewith breast cancer,with relative risks reaching 2.7when
extreme tertiles of estrone were compared. Only a few small stud-
ies of ovarian cancer have been published, and associations with
endogenous estrogen have been inconsistent [6]. For all three can-
cers, the mechanisms of estrogen-mediated carcinogenesis have
yet to be defined, and may differ among the three sites.
2. Estrogen metabolism and cancer
Although experimental, clinical, and epidemiologic research
have implicated endogenous estrogens in the etiology of breast
and endometrial cancer, and possibly ovarian cancer, the role
of individual patterns of estrogen metabolism has been largely
unexplored in epidemiologic work [7]. Metabolism of estro-
gens occurs in the liver and kidneys, and in target tissues, and
includes oxidative metabolism (hydroxylation) and conjugative
metabolism (methylation, sulfation, and/or glucuronidation) [8].
Oxidation of the parent estrogens, estrone and estradiol, occurs
at either the 2-, 4- or 16-position of the carbon skeleton to yield
2-hydroxylated, 4-hydroxylated, or 16-hydroxylated estrogens,
respectively (Fig. 1) [9]. At least 15 human cytochrome P450 iso-
forms, phase I enzymes that vary in their distribution across target
tissues, their catalytic activity, and their specificity, are capable
of catalyzing these hydroxylations [10]. Catechol estrogens, with
adjacent hydroxyl groups at the 2- and 3-positions or the 3-
and 4-positions, can be methylated (Fig. 1), which is generally
considered an excretory pathway [11]. 16-hydroxyestrone can
be further metabolized by reduction and oxidation at the 17-
and 16-positions (Fig. 1). Conjugation with sulfate or glucuronide
moieties is known to modulate the bioavailability of estrogens
and estrogen metabolites (which we refer to jointly as EM).
Sulfation of estrogens may extend the half-life in circulation while
glucuronidation is an important excretory pathway for estrogens.
Estrogen metabolism yields products that are potentially both
estrogenic and genotoxic. Specific estrogen metabolism pathways,
Fig. 1. The estrogen metabolites formed by hydroxylation of the parent estrogens, estrone and estradiol, at the 2-, 4-, or 16-positions of the carbon ring. The relative size of
the chemical structures indicates the relative concentration in urine in premenopausal women, postmenopausal women, and men [18].
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such as formation of the 16-hydroxylated estrogens with their
strong hormonal and mitogenic activity, are postulated to increase
breast cancer risk [12]. Alternatively, specific estrogenmetabolites,
such as the reactive catechol estrogens, may function as carcino-
gens by reacting with DNA to form stable or depurinating adducts
[7] although it has also been postulated that 2-pathway catechol
estrogens may actually be protective since their formation pre-
cludes 16-hydroxylation [13]. The 4-pathway catechol estrogens,
though substantially less abundant, are potent inducers of DNA
damage in animal and in vitro models and have been hypothe-
sized to increase breast cancer risk [14]. Methylation of catechol
estrogens weakens binding to the estrogen receptor, thus reduc-
ing estrogenicity, and prevents reactive quinone formation; both
effects should reduce cancer risk [11]. Estrogen metabolism pat-
terns may also determine how bioavailable estrogen is in target
tissue and how efficiently it is removed from circulation.
3. Liquid chromatography–tandem mass spectrometry
(LC–MS2) assay for estrogens and estrogen metabolites (EM)
Nine years ago, we decided to attempt a “high risk/high reward”
project. The laborious “gold standard”mass spectrometrymethods
for measuring endogenous steroid hormones were being aban-
doned, and the limitations of commercial radioimmunoassay (RIA),
enzyme immunoassay (EIA), and enzyme-linked immunoassay
(ELISA) kits were complicating epidemiologic research on hor-
monal carcinogenesis. Variability over time, between kits, and
among labs frustrated individual and pooled analyses. Each hor-
mone was assayed independently, and required 0.2–1.0mL and
substantial costs per sample. In addition, long-standing hypotheses
about the importance of individual steroid hormone metabo-
lites and patterns of metabolism, based on experimental research,
were not being evaluated in epidemiologic studies. Robust, rela-
tively rapid analytic methods capable of characterizing estrogen
metabolism in the large number of biologic samples collected in
epidemiologic research were required.
In amultidisciplinary effort, Drs. Larry Keefer, Tim Veenstra, Xia
Xu, and Regina Ziegler have collaborated to develop an accurate,
precise, and sensitive high-performance liquid chromatography-
electrospray ionization-tandem mass spectrometry method for
measuring concurrently the endogenous EM in human serum and
urine [15,16]. The procedure is relatively simple and rapid; it
requires hydrolysis, extraction, and a single chemical derivatiza-
tion, andonly0.5mLof serumorurine (Fig. 2). Enzymatichydrolysis
with Helix pomatia extract removes sulfate and glucuronide
Fig. 2. Schematic of liquid chromatography–tandemmass spectrometry procedure
for measuring endogenous estrogens and estrogen metabolites (EM) in serum and
urine samples. Total (conjugated and unconjugated) EM are measured by including
the enzymatic hydrolysis step. Only unconjugatedEMaremeasured if thehydrolysis
step is omitted. The chemical structure for dansylated estradiol indicates how the
1-dimethylamino-naphthalene-5-sulfonyl (dansyl) moiety covalently binds to the
phenolic hydroxyl at the 3-position, a defining characteristic of all EM.
residues from the EM. Omitting the hydrolysis step enables
us to measure the quantities of unconjugated EM. The single
derivatization adds a bulky, charged dansyl (1-dimethylamino-
naphthalene-5-sulfonyl) group to the phenolic hydroxyl at the
3-position on each EM. This reactive hydroxyl, characteristic of all
estrogens, enables our technique to measure not only the parent
estrogens but also all the estrogen metabolites. The dansylation
is critical since mass spectrometry separates and detects com-
pounds on the basis of charge and molecular weight, and does not
perform efficiently with neutral, fat-soluble compounds, such as
steroids. Electrospray ionization is utilized to gently convert com-
plex biological solutions into gas phase ions and link the liquid
chromatography to the mass spectrometer. In order to identify
unique, well-resolved peaks for each EM,many of which are chem-
ically very similar, we incorporate tandem mass spectrometry, in
which a second fragmentation and separation is applied to the ions
generated by the initial fragmentation. Finally, a defining charac-
teristic of our approach is reliance on stable isotope dilution. We
add stable 2H- or 13C-labeled EM standards at the beginning, before
hydrolysis, so that we can quantitatively correct for loss or degra-
dation during all steps of the procedure.
With our LC–MS2 technique, we can simultaneously measure
the absolute quantities of the two parent EM, estrone and estra-
diol; the two catechol and three methylated catechol EM in the
2-hydroxylation pathway (2-hydroxyestrone, 2-hydroxyestradiol
and 2-methoxyestrone, 2-methoxyestradiol, 2-hydroxyestrone-3-
methyl ether); the one catechol and two methylated catechol
EM in the 4-hydroxylation pathway (4-hydroxyestrone and
4-methoxyestrone, 4-methoxyestradiol); and the five EM in
the 16-hydroxylation pathway (16-hydroxyestrone, estriol, 17-
epiestriol, 16-ketoestradiol, 16-epiestriol) (Fig. 1).
Mass spectrometry techniques are increasingly viewed as the
most promising approach for improving sensitivity, specificity,
accuracy, and precision in steroid hormone measurement, and the
“gold standard” againstwhich traditional RIA, EIA, andELISA should
be compared [17]. Our LC–MS2 assays for EM in serum and urine
offer the advantages ofmass spectrometry and, in addition, analyse
parent estrogens and a wide variety of their metabolites in a single
run.
4. EM in urine
In 2005, we published our LC–MS2 technique for the simulta-
neous measurement of the absolute quantities of 15 urinary EM,
which are presented in Fig. 1 [16]. Because EM are mostly present
in urine as glucuronide or sulfate conjugates, we are currently
measuring total EM, the sum of the glucuronidated, sulfated, and
unconjugated forms of each EM. The conjugated EM within each
urine sample are enzymatically hydrolyzed after addition of the
isotopically labelled standards. We start with 0.5mL of urine, and
10% is eventually placed on the column. The lower level of quan-
titation for each EM is 40pg/mL urine (∼150 fmol/mL). The level
of quantitation is the concentration at which we know we have
acceptably low coefficients of variation (CV’s) because of suffi-
ciently high signal-to-noise ratios. Our level of detection, which
is the “sensitivity” reported in the literature for most steroid hor-
mone assays, is ∼4pg/mL urine (∼15 fmol/mL). Accuracy, based on
percent recovery of a known amount of unconjugated EM added to
charcoal-stripped human urine, is 96–107%. Calibration curves are
linear over a 103-fold concentration range. At this point in time, we
are relying on five stable isotopically labeled standards for the 15
EM: deuterated estradiol, 2-hydroxyestradiol, 2-methoxyestradiol,
estriol, and 16-epiestriol.
Using overnight urines from five follicular phase and five luteal
phase premenopausal women, five postmenopausal women, and
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five men, we conducted a formal “proof of performance” of our
urinary EM assay by measuring two randomized, blinded aliquots
fromeach subject in eachof fourbatchesover fourweeks [18].None
of the women were currently using exogenous hormones, such as
oral contraceptives or menopausal hormone therapy. Laboratory
CV’s, which included the hydrolysis, extraction, and derivatization
steps as well as within and between batch variation, were≤10% for
each of the 15 EM, and generally ≤5%. Intraclass correlation coef-
ficients (ICC’s) within each menstrual/sex group, a measure of the
variability attributable to interindividual differences, were gener-
ally ≥0.98. Thus, within each menstrual/sex group, the range in
concentration of each EM was quite large relative to assay vari-
ability. The ICC’s may be somewhat imprecise because of the small
numberof participants in the studybutwere remarkably consistent
across the four menstrual/sex groups.
For descriptive analyses, we combined data from an addi-
tional 25 subjects with the data from these 20 subjects [18].
Although geometric mean EM concentrations (pg EM/mg creati-
nine) differed substantially among the four menstrual/sex groups,
the rankings of the individual EM were quite similar, with
estriol, 2-hydroxyestrone, estrone, estradiol, and 16-ketoestradiol
accounting for 60–75%of total urinaryEM. The three catechol estro-
gens comprised 20–25% of total EM, while the five methylated
catechol estrogens were 5–10%. What was especially exciting was
that within each menstrual/sex group, interindividual differences
in urinary EM concentrations, which reflect interindividual differ-
ences inEMproductionandexcretion,were consistently large,with
a range of 10–100-fold for nearly all EM. This interindividual vari-
ation is highlighted in Fig. 3, which shows box plots of urinary
concentrations of the three catechol EM, the five methylated cate-
chol EM, and thefive 16-pathwayEM for eachmenstrual/sex group.
EM concentration is plotted on a logarithmic scale, with a different
scale for each boxplot.
At this point, we knew that interindividual variability in uri-
nary EM concentrations was substantially larger than laboratory
variation. However, we did not know whether variation in uri-
nary EM levels in an individual over secular time would limit our
ability to identify associations with risk when we relied upon a
single urine collection, as is typical of most epidemiologic stud-
ies. Dr. Sue Hankinson at Harvard School of Public Health had
collected urine samples in the Nurses’ Health Study II cohort
that were appropriate for addressing this question. With Dr.
Heather Eliassen, also at Harvard, we examined the reproducibil-
ity of urinary EM concentrations in 110 premenopausal women
with luteal phase urine samples collected during each of three
years [19]. On average, parent EM (estrone and estradiol) were
21% (5th–95th percentiles =12–34%) of total urinary EM and 2-
pathway, 4-pathway, and 16-pathway EM were 36% (12–62%), 4%
(1–8%), and39% (17–67%), respectively; interindividual variation in
estrogen metabolism was clearly apparent. Reproducibility within
a woman over time was relatively high for the three hydroxylation
pathways, with ICC’s ranging from 0.52 (16-pathway EM) to 0.57
Fig. 3. Interindividual variation in urinary concentrations of catechol estrogens and estrogen metabolites (EM), methylated catechol EM, and 16-pathway EM is shown
with box plots for 10 premenopausal follicular phase women, 10 premenopausal luteal phase women, 15 postmenopausal women, and 10 men. Urinary EM concentrations
are in pg/mg creatinine and presented on a logarithmic scale. The first graph summarizes interindividual variation of the catechol EM, shown in the following order: 2-
hydroxyestrone (2-OHE1), 2-hydroxyestradiol (2-OHE2), and 4-hydroxyestrone (4-OHE1). The second graph summarizes interindividual variation of themethylated catechol
EM: 2-methoxyestrone (2-MeOE1), 2-methoxyestradiol (2-MeOE2), 2-hydroxyestrone-3-methyl ether (3-MeOE1), 4-methoxyestrone (4-MeOE1), and 4-methoxyestradiol (4-
MeOE2). The third graph summarizes interindividual variation of the 16-pathwayEM:16-hydroxyestrone (16-OHE1), 17-epiestriol (17-epiE3), estriol (E3), 16-ketoestradiol
(16-ketoE2), and 16-epiestriol (16-epiE3). The horizontal line within each box is the median of the distribution. The top and bottom of each box are the interquartile range
(75 and 25 percentiles, respectively) of the distribution. The vertical lines above and below each box extend to the extreme values that are not outliers (≤1.5 times the
interquartile range). Outliers are represented as stars (>1.5 but ≤3 times the interquartile range) and open circles (>3 times the interquartile range).
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(4-pathway EM) to 0.72 (2-pathway EM), which were as high as
or higher than the ICC’s for estrone and estradiol (∼0.5). ICC’s for
the individual catechol EMand 2-pathwaymethylated catechol EM
were comparably high. Because of their low concentrations, ICC’s
for the individual methylated catechol EM in the 4-pathway were
relatively low (<0.3). Converting absolute EM concentrations (pmol
EM/mg creatinine) to relative concentrations (pmol EM expressed
as percent of total EM in pmol) noticeably improved the ICC’s.
These data indicate that urinary EM levels do vary substantially
among individuals when compared to intraindividual variability.
It is encouraging that reproducibility in premenopausal women
over time for most individual and grouped EM is comparable to
or better than that of well-vetted biomarkers, such as circulating
cholesterol (ICC=0.65); blood glucose (ICC=0.52); and, in post-
menopausal women, plasma estradiol (ICC=0.68), all of which are
considered to be reliable predictors of disease in epidemiologic
studies [19].
We also evaluated Spearman correlations among the EM [19].
Urinary estrone was only moderately correlated with the indi-
vidual estrogen metabolites (most rs = 0.3–0.6), while correlations
between urinary estradiol and the individualmetabolites were still
lower (rs = 0.1–0.4).However, individual EMwithinapathwaywere
fairly highly correlated. The 2-pathway EM and 4-pathway EM
were highly correlated (rs = 0.9), but both pathways were weakly
and inversely correlatedwith the 16-pathway EM (rs =−0.2). These
data suggest that urinary concentrations of the parent EM, estrone
and estradiol, do not accurately represent the concentrations of
individual estrogen metabolites. Potentially important additional
information is obtained when the entire estrogenmetabolism pro-
file is measured in urine.
In preparation for large-scale epidemiologic studies, we have
studied the stability of the 15 EM in urine samples, with and with-
out added ascorbic acid (0.1% w/v), during (1) interim storage at
4 ◦C, (2) long-term storage at −80 ◦C, and (3) freeze-thaw cycles
[20]. Early morning urine specimens were provided by three pre-
menopausal women.We sawno consistent evidence of >1% loss for
any of the EMduring interim storage for 24h, long-term storage for
one year, or two additional freeze-thaw cycles in the sampleswith-
out added ascorbic acid. Given the large interindividual variability
in urinary EMconcentrationswehave observed [18], these changes
are unlikely to cause substantial misclassification in epidemiologic
research. To our surprise, ascorbic acid, an antioxidant which has
been suggested in the literature as necessary to protect specific EM
[21,22], had no clear beneficial effects on individual EM stability in
any of these experiments. Therefore, for epidemiologic and clini-
cal studies that will be collecting urine samples in which EM will
be measured, we suggest immediately chilling the urine sample to
4 ◦C on collection, or the individual portions of urine if a 12- or 24h
collection is planned; keeping the urine at 4 ◦C for no more than
1–2 days before decanting and aliquotting for long-term storage at
−70 ◦C; and adding no preservatives or antioxidants.
This stability study validated the urine collection and storage
procedures we had already used in several epidemiologic stud-
ies in which we wished to measure EM in prospectively stored
urine samples and assess associations with subsequent cancer.
In epidemiologic studies of endogenous hormones and hormone
metabolism, urine samples offer some distinct advantages over
blood, including ease of biospecimen collection, potentially higher
participation rates, and the integration of exposure over time for
hormones with pulsatile, circadian, or menstrual cycle variability.
5. EM in blood
In 2007, we published the details of our LC–MS2 technique for
the simultaneousmeasurement of the absolute quantities of serum
EM [15]. In exploratorywork, we had found, to our surprise, that all
15 EMwe had detected in urine (Fig. 1) were also present in serum
in conjugated form, as sulfates or glucuronides, and that five of the
EM were present at quantifiable levels in unconjugated, or free,
form. Therefore, to accurately capture the concentration of total
endogenous estrogen in circulation and the concentrations of all
individualEM,wedecided that for serumsamples,wewoulddo two
LC–MS2 analyses: one of total (conjugated+unconjugated) EM and
one of unconjugated EM. Unconjugated EM are measured by elim-
inating the enzymatic hydrolysis step in our method; total EM are
measured by including enzymatic hydrolysis; conjugated EM can
becalculatedas thedifferenceof the twoanalyses. Toenhanceaccu-
racy, stable isotopically labeled EM standards are added to 1.0mL
serum samples. Two 0.4mL aliquots are created from each 1.0mL
sample; only one of the two aliquots is hydroyzed. Both aliquots
are then extracted, derivatized, and analysed independently by
LC–MS2.
Except for the change described above, where wemeasure both
total and unconjugated EM in each sample, our method for mea-
suring all 15 EM concurrently in serum is similar to our method
for urinary EM. A total of 1.0mL of serum is required to measure
both total and unconjugated EM. We currently use newer LC–MS2
systems for the serum analyses than the urine analyses, which
has resulted in a 5-fold increase in sensitivity. The lower level of
quantitation for each EM is 8pg/mL serum (26.5–29.6 fmol/mL).
The level of detection, which is the “sensitivity” reported in the
literature for most steroid hormone assays, is ∼0.8pg/mL serum
(<3 fmol/mL). Accuracy, based on recovery of a weighed amount of
unconjugated EM added to charcoal-stripped serum, is 91–113%.
Calibration curves are linear over a 103-fold concentration range.
Weare currently relying on six stable isotopically labeled standards
for the 15 EM: deuterated 2-hydroxyestradiol, 2-methoxyestradiol,
estriol, and 16-epiestriol and C-13 labeled estrone and estradiol.
We have not yet completed stability studies of individual EM
in serum during interim and long-term storage comparable to the
stability studieswe performed for urinary EM. For serum collection
and storage, we use the protocol adopted by most epidemiologic
studies. Blood is kept at room temperature for no more than an
hour as it clots; the serum is collected by pipetting or decanting
after centrifugation. Once the serum is aliquotted, it is stored at 4 ◦C
for nomore than 12h, and then transferred to−70 ◦C for long-term
storage. No antioxidants or preservatives are used. It is generally
accepted that parent EM in serum or plasma are stable for up to 3
days during interim storage at 4 ◦C, and for years during long-term
storage at −70 ◦C. [23].
It is the extremely high sensitivity of our LC–MS2 assay—a
level of quantitation for each EM of 8pg/mL serum and a level of
detection of ∼0.8pg/mL serum—that enables us to measure circu-
lating estrogens in postmenopausal women. Distinguishing serum
estradiol levels in the low postmenopausal range (<30pg/mL;
<110 fmol/mL) is an important prognostic tool for common chronic
diseases of older women, specifically breast cancer, osteoporosis,
cardiovascular disease, and possibly cognitive dysfunction [24].
The ability to measure serum estradiol with high sensitivity and
specificity is particularly important inmonitoring postmenopausal
women with hormone-dependent breast cancers who are receiv-
ing aromatase inhibitors. Suppression of estrogen production may
be influenced by non-compliance, hidden drug–drug interactions,
and genetically altered pharmacokinetics and can promote severe
bone loss [25]. Both indirect RIAmethods,which include extraction
and/or chromatography, and direct RIA methods are not accurate
or sensitive enough to monitor serum estradiol at these low lev-
els [25]. Bioassays that rely on recombinant yeast methods and
HeLa cells may be more sensitive than RIA but lack specificity and
convenience [25]. Gas chromatography/tandem mass spectrome-
try provides the needed specificity, sensitivity, and accuracy, but
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Fig. 4. Mean serum concentrations of unconjugated and conjugated forms of
15 estrogens and estrogen metabolites (EM) in eight postmenopausal women.
Serum concentrations, in fmol/mL, are plotted on a logarithmic scale. Conju-
gated forms of each EM are represented by the white section of the bar graph;
unconjugated forms are represented by the dark section of the bar graph. Total
concentration of each EM is represented by the entire bar graph. The stan-
dard error of the mean for total EM concentration is shown by the thatch
marks. Parent EM include estrone (E1) and estradiol (E2). 2-pathway EM include
2-hydroxyestrone (2-OHE1), 2-hydroxyestradiol (2-OHE2), 2-methoxyestrone (2-
MeOE1), 2-methoxyestradiol (2-MeOE2), and 2-hydroxyestrone-3-methyl ether
(3-MeOE1). 4-pathway EM include 4-hydroxyestrone (4-OHE1), 4-methoxyestrone
(4-MeOE1), and 4-methoxyestradiol (4-MeOE2). 16-pathway EM include 16-
hydroxyestrone (16-OHE1), estriol (E3), 17-epiestriol (17-epiE3), 16-ketoestradiol
(16-ketoE2), and 16-epiestriol (16-epiE3).
does not match the tight CV’s of our LC–MS2 method [25]. How-
ever, before anymass spectrometrymethod canbeused in a clinical
environment to measure estradiol or other EM, detailed reference
protocols, calibration and validation requirements, and normative
values need to be developed [26].
We have completed a formal “proof of performance” for our
serum EM assay in eight postmenopausal women not on hormone
therapy. Two samples fromeach of the eightwomenwere analysed
during each of four weeks. Laboratory CV’s were ≤5% for all total
and unconjugated EM, except for the two EM at the lowest concen-
trations: total 4-methoxyestradiol (CV=6%) and total 17-epiestriol
(CV=7%).
The descriptive data from this “proof of performance” were
intriguing, and are summarized in Fig. 4. This bar graph shows for
all 15 EM the mean serum concentrations, in fmol/mL, of conju-
gated, unconjugated, and total EM for the eight postmenopausal
women. Concentrations are shown on a logarithmic scale, and the
standard error of the mean for total EM is included. In general,
only circulating levels of estrone sulfate, estrone, and estradiol are
measured in epidemiologic and clinical studies. However, these
three EM are just a fraction of the physiologic complexity. In all
these women, all 15 EM we had previously characterized in urine
were also present in serum. The molar concentration in serum of
all 15 EM combined was generally more than three times that of
estrone sulfate, a biologically inactive estrogenwhich is thought to
be the estrogen reservoir and canbe converted to estrone andestra-
diol in breast and other target tissues [27]. For each of the 15 EM,
the molar concentration of the conjugated form was substantially
higher than the molar concentration of the unconjugated form; in
fact, we detected only five unconjugated EM in circulation: estrone,
estradiol, estriol, 2-methoxyestrone, and 2-methoxyestradiol. We
could not detect any of the potentially mutagenic and genotoxic
catechol estrogens in circulation. Estradiol itself, considered the
biologically active form of estrogen and the predominant activa-
tor of estrogen receptor-mediated cellular processes, was more
abundant conjugated than unconjugated in most of the women.
Conjugated estradiol is not currently measured by the indirect or
direct RIA assays for estradiol so its influence is generally not eval-
uated. Yet conjugated estradiol concentrations may be biologically
relevant since breast and other tissues contain sulfatases and glu-
curonidases that can generate biologically active estradiol from
conjugated estradiols in circulation. Evidence is increasing that sul-
fation/desulfationof EMrepresents a cyclic system important in the
regulation of biologically active estrogen in target tissue,while glu-
curonidation is the major pathway for estrogen excretion in urine
and bile [8,28].
We are currently expanding this “proof of performance” for
our serum EM assay to include premenopausal women and men.
While the laboratory CV’s will be interesting, the descriptive data
for total, conjugated, and unconjugated EM in circulation may well
be unique.
In trying to measure patterns of endogenous estrogen
metabolism, we have focused on 15 specific EM in conjugated and
unconjugated form, primarily the EM reported in early studies of
urinary EM. It is these EM for which we routinely include purified
standards in all our LC–MS2 runs. In the future, we will have the
opportunity to modify our method and utilize it to identify addi-
tional EM present in human urine and serum, including those due
to rare gene variants, environmental and lifestyle exposures, and
disease/treatment. We have not yet used the structure identifica-
tion properties ofmass spectrometry to identify provocative peaks,
nor have we obtained a library of standards for additional EM that
might be present.
6. Comparing EM measurement by RIA or ELISA and by
LC–MS2
Absolute and relative EM concentrations are important for clin-
ical decisions, as well as epidemiologic and experimental research
on hormonal carcinogenesis. RIA, EIA, and ELISA are routinely
used for measuring EM in blood and urine because of their effi-
ciency, simplicity, and low cost. We wanted to compare these
widely accepted, commercially available methods with our new
LC–MS2 technique. In a population-based case-control study of
breast cancer in Asian–American women aged 20–55 years [29],
we had measured five EM in 12h overnight urines collected
from 362 premenopausal and 168 postmenopausal controls. We
had chosen state-of-the-art methods and experienced laboratories
widely used by epidemiologists and clinicians. Estrone, estradiol,
and estriol were assayed at Nichols Institute (San Juan Capis-
trano, CA)with an indirectmethod involving enzymatic hydrolysis,
extraction, chromatography, and RIA [30]. 2-Hydroxyestrone and
16-hydroxyestrone were assayed at Strang Cancer Research
Laboratory (New York, NY) with a method involving enzymatic
hydrolysis and ELISA [31,32]. Recently we re-assayed the same
urines with our LC–MS2 method and compared the absolute and
relative results with those obtained earlier by RIA and ELISA [33].
For the premenopausal women, ranking subjects by RIA-based
measures of urinary estrone, estradiol, and estriol agreed quitewell
with those obtained using LC–MS2 (rs > 0.9), while ranking subjects
by ELISA-based measures of urinary 2-hyroxyestrone and 16-
hydroxyestrone agreed reasonably well with LC–MS2 (rs = 0.8–0.9)
(Table 1). However, for the postmenopausal women, agreement
was noticeably reduced for all five EM (rs = 0.4–0.8).
Geometric mean concentrations (pmol/mg creatinine) of
estrone, estradiol, and estriol were 1.4–1.9 times higher by RIA
than LC–MS2 in premenopausal women, and 1.4–2.7 higher in
postmenopausal women (all p<0.0001) (Table 1). Geometric mean
concentrationsof2-hydroxyestroneand16-hydroxyestronewere
2.0–3.7 times higher by ELISA than LC–MS2 in premenopausal
women, and 2.7–11.8 times higher in postmenopausal women (all
p<0.0001). These data suggested the RIA and ELISA assays had lim-
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Table 1
Comparison of urinary estrogen/estrogen metabolite (EM) measurement by RIA/ELISA and LC–MS2: Spearman correlations and absolute concentrationsa.
EM Premenopausal
luteal phase women
Premenopausal
non-luteal phase women
Postmenopausal
women
N=264 N=98 N=168
Spearman correlations
RIA and LC–MS2
Estrone 0.94 0.96 0.79
Estradiol 0.91 0.95 0.63
Estriol 0.94 0.94 0.73
ELISA and LC–MS2
2-Hydroxyestrone 0.81 0.89 0.37
16-Hydroxyestrone 0.86 0.89 0.62
Geometric mean concentrations (pmol/mg creatinine)
RIA or ELISA/LC–MS2 RIA or ELISA/LC–MS2 RIA or ELISA/LC–MS2
RIA and LC–MS2
Estrone 41.9/23.4 27.9/14.6 6.9/2.6
Estradiol 17.6/10.9 12.0/7.7 2.1/1.5
Estriol 77.2/55.5 50.1/31.2 12.9/5.7
ELISA and LC–MS2
2-Hydroxyestrone 47.8/24.6 31.0/13.8 18.6/2.9
16-Hydroxyestrone 32.2/11.0 23.8/6.5 14.1/1.2
a Subjects are Asian–American women, aged 20–55 years, selected as controls for a population-based case-control study of breast cancer [29]. 12h overnight urines were
collected.
ited specificity and accuracy, and were detecting additional EM or
other steroids.
Based on the blinded quality control samples that we had
inserted for all the assays, laboratory CV’s for estrone, estradiol,
and estriol were ≤13% for RIA in premenopausal women, ≤18% for
RIA in postmenopausal women, and ≤5% for LC–MS2 in both pre-
menopausal and postmenopausal women [33]. Laboratory CV’s for
2-hydroxyestrone and16-hydroxyestronewere≤14% for ELISA in
bothpremenopausal andpostmenopausalwomen,≤5% for LC–MS2
in premenopausalwomen, and≤9% for LC–MS2 in postmenopausal
women. Thus, our results for reproducibility, as well as accuracy,
indicated that the widely used RIA and ELISA measures for EM
might be problematic, particularly at the low concentrations char-
acteristic of postmenopausal women. Although this comparison of
state-of-the-art commercial assays with LC–MS2 was performed
with urine samples, it is plausible that in serum, a more compli-
catedmatrix, the commercial assays would perform even less well,
relative to LC–MS2.
7. Future directions
We continue to optimize our EM LC–MS2 methods and refine
them for the demands of large-scale epidemiologic research. We
are concentratingon three issues. (1)At present,weareusing either
fiveor six stable isotopically labeled standards inour LC–MS2meth-
ods for measuring 15 EM. In our laboratory, as soon as urines or
sera are defrosted for assay, we add the stable isotopically labeled
EM standards so that we can correct quantitatively for loss and
degradation. Ideally, stable isotope dilution requires a distinct iso-
topically labeled standard for each analyte so that we do not need
to extrapolate results from structurally similar, but not structurally
identical, compounds.Wehavenowacquired12C-13 labelled stan-
dards andwill be testing and incorporating them intoour assays. (2)
Our current throughput per week on one LC–MS2 system is only 40
unknowns (which includes ∼4 blinded quality control samples) + 8
known quality control samples +14 samples for two calibration
curves =62 samples, only 58% of which are really unknowns. We
can receive “real-time” information each week on assay perfor-
mance from the known quality control samples. Nonetheless, this
throughput means that it would require 25 weeks on each of two
LC–MS2 systems to measure both total and unconjugated EM con-
centrations in 1000 serum samples. Clearly, throughput needs to
be improved. We are currently testing some faster liquid chro-
matography systems potentially capable of increasing throughput
3-fold. (3) We have established standard operating procedures
for our methods and carefully described the optimized tech-
niques in publications. However, to the extent that personnel may
need practical “hands-on” experience before they can successfully
implement the assays, we need to clarify, and possibly simplify, our
procedures.
While our LC–MS2 methods for measuring EM in serum and
urine are still being improved, they have been validated and are
robust and rapid and, therefore, appropriate for epidemiologic
work. We can assess total estrogen exposure, concentrations of
specific EM, and individual patterns of estrogen metabolism in
epidemiologic studies. In a population-based case-control study
of breast cancer in Asian–American migrants, we have explored
the relationship between urinary EM and Westernization in the
controls. Within these controls, Westernization predicts a 6-fold
gradient in risk of breast cancer, comparable to the historic inter-
national differences in breast cancer incidence between Asia and
the U.S. [29]. We have completed two nested case-control studies
of EM and breast cancer in large cohorts. The first, in collaboration
with Drs. Hankinson and Eliassen, is of premenopausal breast can-
cer and utilizes prospectively stored urines from theNurses’ Health
Study; the second is of postmenopausal breast cancer and utilizes
prospectively stored serum samples from the Prostate, Lung, Col-
orectal, and Ovarian Cancer Screening Trial (PLCO) cohort. We are
designing a nested case-control study of endometrial cancer and
circulating EM that will pool biospecimens from PLCO and other
cohorts. In collaboration with Drs. Kala Visvanathan and James
Yager at Johns Hopkins School ofMedicine, we are testingmethods
to measure EM in breast tissue and will examine the relationships
among conjugated and unconjugated EM in breast tissue, blood,
and urine.
Our LC–MS2 methods for measuring concurrently 15 EM in
serum and urine provide outstanding accuracy, precision, sensi-
tivity, and specificity. However, the methods are still relatively
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labor-intensive and time consuming. We hope to apply our meth-
ods in important epidemiologic research where the quality of the
study design and potential impact of the results justify the use of
our methods. We anticipate that the application of our techniques
in epidemiologic research will inform further modification of our
methods. Perfecting a method should not be an end in itself. Most
important, the results from our expanding portfolio of epidemio-
logic studies that have utilized these methods should help clarify
the roleof endogenousestrogenexposureandestrogenmetabolism
in the etiology of cancer.
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